Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Fate Therapeutics, Inc. - Common Stock
(NQ:
FATE
)
1.550
-0.100 (-6.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 27, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
January 25, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE
January 25, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Analyst Ratings for Fate Therapeutics
January 24, 2023
Via
Benzinga
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)
January 24, 2023
From
Robbins LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 24, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate
January 24, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
January 24, 2023
Via
Benzinga
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 24, 2023
From
The Schall Law Firm
Via
Business Wire
FATE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
January 23, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 23, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 23, 2023
From
Kirby McInerney LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 23, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
January 23, 2023
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
January 23, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 23, 2023
From
The Schall Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 19, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
5 Health Care Stocks That Are Diving - And May Rally
January 19, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
January 18, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 18, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
January 18, 2023
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Via
MarketBeat
Topics
Stocks
The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 17, 2023
From
Law Offices of Frank R. Cruz
Via
Business Wire
Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying
January 17, 2023
Although US stocks closed higher on Friday, there were a few notable insider trades.
Via
Benzinga
FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm
January 11, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Top 5 Health Care Stocks That May Surge
January 10, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
How Is The Market Feeling About Fate Therapeutics?
January 09, 2023
Fate Therapeutics's (NASDAQ:FATE) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 20.24 million shares sold short, which is 27.85% of all...
Via
Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 09, 2023
From
The Schall Law Firm
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today